Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%
HOUSTON, April 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, announced that Walter Klemp, Chairman and Chief Executive Officer, will host a web-based conference call on April 16th at 4:30pm ET to explain the significance of the recent discovery that the active compound in WP1122 has been shown to reduce replication of SARS-CoV-2 by 100%.
finance.yahoo.com/news/...stor-conference-call-113000351.html